1. 474O Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC. (24th November 2019) Authors: Cho, B C; Lee, K H; Ahn, M-J; Geater, S Lucien; Ngoc, T V; Wang, C-C; Cho, E K; Lee, J S; Sriuranpong, V; Bui, Q; Clarke, S; Kuyama, S; Nakagawa, K; Liu, F; Clemett, D; Scheuring, U; Peters, S; Rizvi, N Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗